世界肺癌大会（World Conference on Lung Cancer，WCLC）是一个专注于肺癌领域的国际性学术会议，由国际肺癌研究协会（International Association for the Study of Lung Cancer，IASLC）主办。该会议每年举办一次，旨在为全球肺癌领域的医生、研究人员、护士、政策制定者和行业代表提供一个交流最新科学研究成果、分享临床实践经验以及讨论肺癌治疗和预防的平台。2024年WCLC将于2024年9月7日至10日在美国加利福尼亚州圣地亚哥举行，同IASLC将在这里庆祝其成立50周年。
在2024年WCLC暨IASLC成立50周年学术活动中，广东省人民医院共有1人次担任session chair，4项受邀主题演讲，49项成果入选本次会议（见下文附表），包括突破性研究（Late Breaking Abstract）2项，口头汇报（Oral）2项，迷你口头汇报（Mini Oral）4项，壁报（Poster）17项，电子壁报（E-Poster）23项；另有3人获得发展中国家奖（Developing Country Award）<张潮、林一多、陈丽娜>，3人获得导师奖（Mentorship Award）<邱镇斌、邓嘉怡、梁庆>。以上成绩离不开广东省人民医院 广东省肺癌研究所团队的共同努力，期待团队在2024年 WCLC发出的中国声音！
吴一龙 | Resecting Residual Disease | Session chair /Invited speaker |
吴一龙 | Joint lASLC-CSCO-CAALC Session | Session chair |
钟文昭 | Novel Immunotherapies | Invited speaker |
钟文昭 | Interim Analysis of a Phase 2 Prospective Trial of Induction Lorlatinib in Locally Advanced ALK Positive NSCLC(LORIN) | Invited speaker |
刘思阳 | Immunotherapy for Lung Cancer: What Is on the Horizon? | Invited speaker |
杨衿记 | Osimertinib With or Without Savolitinibas 1L in De Novo MET Aberrant, EGFRm Advanced NSCLC (CTONG 2008): A PhaseIl Trial | Late Breaking Abstract (Presidential symposium oral presentation) |
张潮 | A Phase 2 Trial of Neoadjuvant Sintilimab Plus Chemotherapy in Localized EGFR-mutant NSCLC (CTONG2104): Prespecified Interim Analysis | Late Breaking Abstract |
周清 | KRAS G12C inhibitor IBI351 in patients (pts) with advanced non-small cell lung cancer (NSCLC): updated results from a pivotal phase 2 study | Oral |
傅睿 | Pre-Local Consolidative Therapy Circulating Circulating Tumor DNA Defines Molecular Oligometastatic Non-Small Cell Lung Cancer | Oral |
陈华军 | A Phase ll Study of Lorlatinib in Advanced ROS1+ NSCLC Pre-treated with Crizotinib and Platinum Based Chemotherapy | Mini Oral |
郑媚美 | Proteogenomic Analysis of CSF Reveals Distinct Molecular Patterns of Leptomeningeal Metastases in EGFR-Mutated NSCLC | Mini Oral |
张嘉涛 | Follow-Up Update of Molecular Residual Disease in Localized Non-Small Cell Lung Cancer | Mini Oral |
林一多 | Genomic Mapping of Evolutionary from Pre-invasive to Advanced Stage in Lung Adenocarcinoma | Mini Oral |
涂海燕 | Clinical outcomes of advanced HER2 mutated NSCLC treated with first-line immune checkpoint inhibitors, with or without chemotherapy | Poster |
潘燚 | Predicting Tumor Recurrence Risk in Locally Advanced NSCLC with detectable ctDNA-Based Molecular Residual Disease: An XGBoost Model Analysis | Poster |
黄婕 | Genotyping of RB1 Status Identifies Two Distinct Subtypes in EGFRMutant Lung Cancers with SCLC Transformation | Poster |
黎扬斯 | First Line Camrelizumab for Brain Metastases of NSCLC (CTONG 2003): A Randomized Controlled Trial | Poster |
刘思阳 | MRD guiding treatment after aumolertinib induction therapy for EGFRm+ stage III NSCLC in the MDT diagnostic model (APPROACH) | Poster |
刘思阳 | Optimal Cut-off with NGS for MET Amplification and Clinical Relevance to MET inhibitor in Non-small-cell Lung Cancer | Poster |
张嘉涛 | Adherence to Clinical Practice Guideline - Analysis of 89 Multidisciplinary Team Discussed Patients with Stage III Lung Cancer | Poster |
邱镇斌 | Limited Efficacy of Immunochemotherapy in Pulmonary Invasive Mucinous Adenocarcinoma and Mucoepidermoid Carcinoma as Neoadjuvant Setting | Poster |
陈丽娜 | Clinical Outcomes of Transformed Small-cell Lung Cancer versus Extensive Primary Small-cell Lung Cancer | Poster |
齐一凡 | Deep Learning-based Whole Slide Image Analysis Predicts PD-L1 Status from H&E-stained Histopathology Images in Lung Cancer | Poster |
洪慧昭 | Spatial memory B cells activation by CXCL13+ Th cells via the MIF(CD74-CXCR4) axis may improve immunotherapy efficacy in HER2 mutant NSCLC | Poster |
黄泽凯 | Pathological Grading of Early-stage Lung Cancers Through CT-to-PET Translation and Co-learning Model | Poster |
侯恒亮 | An Enhanced Immunotherapeutic Strategie for NSCLC via In Situ Tumor nanovaccines and Activation of STING and TLR7/8 Pathways | Poster |
黄钰程 | NIR-II Mediates Cancer Nanocomposite Vaccines for Lymph Node Targeted Delivery and Enhanced Immunotherapy | Poster |
邱鸿锐 | Augmenting Post-Surgical Tumor Immune Response and Recurrence Prevention via Nanoparticle-Assisted Targeted Drug Delivery | Poster |
林泽楠 | Enhancement of Chemotherapy and Immunotherapy in LUSC Animal Models through Tumor Microenvironment Remodeling by Losartan | Poster |
黄树杰 | Association Between Dynamic Patient-Reported Outcome-Based Symptom Exacerbation and Postoperative Complication in Lung Cancer | Poster |
邓嘉怡 | Patterns of failure and subsequent treatment after progression on first-line immunotherapy monotherapy in advanced NSCLC | E-poster |
梁庆 | Investigation on the Incidence And Risk Factors of Lung Cancer Among Chinese Hospital Employees | E-poster |
康劲 | Genomic and Disease-specific Hallmarks of Extrachromosomal Circular DNAs in Lung Cancer and Its Potential Role in Cancer Progression | E-poster |
陈梓豪 | A novel lung nodule localize method:Topographic Map dyeing model for Target vessel watershed boundary | E-poster |
林嘉欣 | A Patient-Centric,Phase l Trial of First-line Lorlatinib&alk TKls in China Advanced ALK+ Non-Small CelLung Cancer | E-poster |
张一辰 | Three-stage evolution of Lung Cancer Multidisciplinary Team in China | E-poster |
张一辰 | Heterogeneous germline variants detected in EGFR-mutant familial lung cancer patients and family members | E-poster |
林俊涛 | Adjuvant immunotherapy is associated with impaired disease-free survival in early stage NSCLC that received neoadjuvant immunotherapy | E-poster |
陈志勇 | Investigating Surgery's Role in Stage IIB-IIIB Small Cell Lung Cancer Following Chemo-immunotherapy | E-poster |
尹凯 | Immune Checkpoint Inhibitors-based Therapy in HER2-mutant NSCLC with Brain Metastases | E-poster |
刘建威 | Durable Response to Savolitinib in Advanced EGFR-WT NSCLC with MET Amplification: Case Series | E-poster |
吴莜 | Tubeless Strategy after Thoracoscopic Pulmonary Wedge Resection: a Better Choice for Specific Patients | E-poster |
吴莜 | Superiority of Modified-MPR in Prediction of Survival for Patients with Lung Cancer after Neoadjuvant Therapy | E-poster |
姜林强 | Induction of Crizotinib Treatment Pre- and Post-Surgery in Advanced Non-Small Cell Lung Cancer Harboring ROS1 Fusions | E-poster |
彭丽珊 | A nomogram prediction model for assessing the risk of recurrence in NSCLC patients underwent neoadjuvant immunotherapy: a retrospective study | E-poster |
许子宜 | Macrophage polarization states predicting the efficacy of neoadjuvant chemoimmunotherapyin resectable or potentially resectable NSCLC | E-poster |
丁佳妍 | Salvage Surgery Following Induction Therapy for Advanced ALK-Positive NSCLC: Pathological Response and Surgical Outcomes | E-poster |
李泓基 | Radiomics-based Clustering Distinguishes Molecular Events Driving Progression of Lung Adenocarcinoma | E-poster |
李洽轩 | Heterogeneity Model for Predicting Radiosensitivity in NSCLC Based on Single Cell Atlas and Radiogenomics | E-poster |
詹炜杰 | Clinical Outcomes of Neoadjuvant Immunotherapy in Stage I-II Non-small Cell Lung Cancer: A Real-world Study and Meta-analysis | E-poster |
姚霖彤 | AI models for intraoperative diagnosis based on surgical resection images in stage IA LUAD: a prospective, multicentric study | E-poster |
吴少伟 | Heterogeneity of Peripheral Blood Cell Dynamics and Oncologic Outcomes between LUAD and LUSC Receiving Neoadjuvant Immunochemotherapy | E-poster |
黄卢煜 | Adequate Subxiphoid Extension of Unilateral Robotic Extended Thymectomy for Large Thymoma | E-poster |
苏公网安备32059002004080号
